Sign in and upgrade to a paid plan to export NAV history as CSV.
Sign in and upgrade to a paid plan to export fund holdings as CSV.
Sign in and upgrade to a paid plan to export insider/SAST/pledge disclosures as CSV.
Sign in and upgrade to a paid plan to export fund holdings as CSV.

Bharat Immunologicals & Biologicals

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524663
₹7.53
Oct. 5, 2026 · BSE · bse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

CompanyMarket cap (₹ Cr)PE (TTM)ROE1Y returnDiv. yieldQualityValuationMomentum
Sun Pharmaceutical Industries Limited 427,010 143.5 13.7% 7.6% — 72 8 30
Divi's Laboratories Limited 244,125 83.0 15.3% 57.8% 0.33% 70 4 51
Torrent Pharmaceuticals Limited 161,506 77.7 12.2% 35.3% 0.80% 56 0 31
Zydus Lifesciences Limited 113,616 32.6 17.3% 14.5% 0.09% 74 24 84
Cipla Limited 107,888 35.1 11.2% -11.7% 0.97% 73 29 62
Laurus Labs Limited 106,505 122.0 17.1% 128.4% — 78 24 53
Mankind Pharma Limited 102,382 46.9 11.7% 0.9% — 68 12 86
Dr. Reddy's Laboratories Limited 100,411 150.9 10.9% -3.7% — 62 33 71

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet. EBITDA = PBT + interest + depreciation.

Enterprise value
Data unavailable.
EV / EBITDA
Data unavailable.
EV / Sales
Data unavailable.
Market cap / Sales
Data unavailable.
Earnings yield
Data unavailable.

Quarterly Financials

↓ Negative
Quarterly Revenue

Dec 2022 quarterly revenue is Rs 0 Cr, down 99.4% YoY.

↑ Positive
Quarterly Net Profit

Dec 2022 quarterly net profit is Rs -5 Cr, up 1323.4% YoY.

Period endRevenue (₹ Cr)PBT (₹ Cr)Net profit (₹ Cr)Basic EPS
Dec. 31, 2022 0 -6 -5 ₹-1.0800
Sept. 30, 2022 26 -4 -3 ₹-0.7100
Dec. 31, 2021 17 -0 -0 ₹-0.0800
Sept. 30, 2021 25 -5 -9 ₹-2.1700
June 30, 2021 14 0 2 ₹0.4500
Dec. 31, 2020 25 -2 -2 ₹-0.4400
Sept. 30, 2020 25 -6 -4 ₹-0.9000
June 30, 2020 19 -1 -1 ₹-0.1800
Dec. 31, 2019 28 -3 -2 ₹-0.5400
Sept. 30, 2019 8 -8 -6 ₹-1.2800
June 30, 2019 7 -5 -3 ₹-0.8000
March 31, 2019 71 -3 -2 ₹-0.5200
Dec. 31, 2018 8 0 0 ₹-0.5800

Quarterly income statement (standalone, ₹ Cr)

IndicatorDec 22Sep 22Dec 21Sep 21Jun 21Dec 20Sep 20Jun 20Dec 19Sep 19Jun 19Mar 19Dec 18
Total income (before exceptional items)0271825142625192989738
Operating revenue0261725142525192887718
Other income0000010-100220
Operating expenses529162813273019301513758
Operating profit-5-21-31-2-41-2-7-6-40
Operating profit margin—-9.4%5.8%-14.1%7.3%-9.0%-17.7%3.3%-7.1%-82.6%-81.9%-6.0%5.5%
Depreciation0000000000000
Interest2221111121110
Exceptional items, gain / (loss)—————————————
Profit before tax-6-4-0-50-2-6-1-3-8-5-30
Tax-2-1-05-2-1-2-0-1-2-2-10
Net profit-5-3-0-92-2-4-1-2-6-3-20
EPS-1.08-0.71-0.08-2.170.45-0.44-0.90-0.18-0.54-1.28-0.80-0.52-0.58
Net profit (TTM)-17-11-10-13-5-9-13-12-14-11-8-6-5
EPS (TTM)-4.04-2.51-2.24-3.06-1.07-2.06-2.90-2.80-3.14-3.18———

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

IndicatorCAGR 3YCAGR 5YMar 19Mar 18Mar 17Mar 16Mar 14
Total income (before exceptional items) -12.6% -16.0% 86†36†126†129†206†
Operating revenue -13.2% -16.2% 84†35†124†128†203†
Other income — — 3†2†1†1†3†
Operating expenses — — 93†—111†131†182†
Operating profit — — -9†—13†-3†21†
Operating profit margin — — -10.6%†—10.3%†-2.4%†10.2%†
Depreciation — — 0†0†0†1†1†
Interest — — 1†—3†2†5†
Exceptional items, gain / (loss) — — 0†0†0†0†0†
Profit before tax — — -8†-8†9†-8†13†
Tax — — -2†-3†——5†
Net profit — — -6†-5†7†-5†9†
EPS — — —————

† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

RatioMar 19Mar 18Mar 17Mar 16Mar 14
Operating margin-10.6%†—10.3%†-2.4%†10.2%†
EBIT margin-7.8%†—9.8%†-4.1%†9.0%†
PBT margin-9.6%†-22.7%†7.6%†-5.9%†6.6%†
Net margin-6.6%†-14.9%†5.4%†-4.2%†4.4%†
Interest coverage-4.40x†—4.52x†-2.19x†3.79x†
Dividend payout—————
Earnings retention—————
Current ratio—————
Quick ratio—————
Debt to equity—————
Return on equity—————
Return on assets—————
Return on capital employed—————
Asset turnover—————

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Data unavailable (only available from the NSE iXBRL feed's coverage period).

Balance Sheet (standalone)

Data unavailable (only available from the NSE/BSE annual filing feeds' coverage period).

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.